Target intelligence / Profile preview

CD8 antigen (human) (CD8)

Target
CD8
Molecular classification
Receptor, Immunoglobulin superfamily, Cell surface glycoprotein, Co-receptor
01

Overview

The CD8 antigen is a transmembrane glycoprotein complex found primarily on the surface of cytotoxic T lymphocytes, serving as a co-receptor for the T-cell receptor (TCR) and mediating immune recognition of antigens presented on major histocompatibility complex class I (MHC-I) molecules. In humans, CD8 exists as a heterodimer of two chains, CD8A (alpha) and CD8B (beta), both encoded on chromosome 2. The primary function of CD8 is to enhance antigen recognition and T cell activation by binding to the invariant α3 domain of MHC-I molecules, facilitating signaling and cytotoxic activity. CD8 is widely used as a biomarker for cytotoxic T cells in research, diagnostics, and monitoring of immunotherapeutic responses. Direct pharmacological targeting of CD8 is rare, but its expression and function are central to strategies in cancer immunotherapy and infection management due to its critical roles in immune surveillance and cytotoxicity.

Other names
CD8CD8A (CD8 alpha chain)CD8B (CD8 beta chain)T-cell surface glycoprotein CD8 alpha chainT-cell surface glycoprotein CD8 beta chainCluster of Differentiation 8
02

Mechanism of action

Null (CD8 is a marker and co-receptor rather than a direct pharmacological target; drugs modulate CD8 function indirectly via immunotherapies or depleting antibodies)

03

Biological functions

Immune responseAntigen recognitionT cell signalingT cell maturation
04

Disease associations

CancerInfectionInflammationAutoimmune diseasesImmune deficiency
05

Safety considerations

Depletion or functional alteration of CD8+ T cells can lead to immunosuppression or impaired anti-viral and anti-tumor immunityTargeting CD8 therapeutically risks unintended immune modulation
06

Interacting drugs

Null (no direct CD8-targeting drugs approved; some investigational therapeutics and antibody-based agents exist, but anti-CD8 therapeutics are not standard clinical agents)
07

Biomarkers

Marker for cytotoxic T lymphocytes (CD8+ T cells) in cancer immunotherapy, infectious disease, and immune disordersUsed for patient selection/monitoring in immunotherapy trials

Beyond the preview

Go deeper on CD8 antigen (human) (CD8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD8 antigen (human) (CD8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call